U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H18FN5O
Molecular Weight 375.3989
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LINIFANIB

SMILES

CC1=CC(NC(=O)NC2=CC=C(C=C2)C3=C4C(N)=NNC4=CC=C3)=C(F)C=C1

InChI

InChIKey=MPVGZUGXCQEXTM-UHFFFAOYSA-N
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)

HIDE SMILES / InChI
Molecular Formula C21H18FN5O
Molecular Weight 375.3989
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Linifanib (ABT-869) is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families, but has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) does not have a general antiproliferative effect due to its high dose requirement. However, it may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3). Linifanib (ABT-869) was in phase III clinical trial for the treatment of hepatocellular carcinoma, but the study failed to meet the primary end point.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 4.0 nM [IC50]
Inhibitor
8297
 3.0 nM [IC50]
Inhibitor
8297
 66.0 nM [IC50]
Inhibitor
8297
 4.0 nM [IC50]
Inhibitor
8297
 3.0 nM [IC50]
Inhibitor
8297
 14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
LINIFANIB

Approved Use

Unknown
Primary
Phase II
1132
LINIFANIB

Approved Use

Unknown
Primary
Phase II
1132
LINIFANIB

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
0.3 mg/kg 1 times / day multiple, oral
MTD
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
DLT: Proteinuria, Hypertension...
Dose limiting toxicities:
Proteinuria (grade 3, 33.3%)
Hypertension (grade 3, 66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
unhealthy, ADULT
n = 74
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 74
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
Disc. AE: Proteinuria, Palmar-plantar erythrodysesthesia syndrome...
AEs leading to
discontinuation/dose reduction:
Proteinuria (10.8%)
Palmar-plantar erythrodysesthesia syndrome (9.5%)
Hypertension (10.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22382879
Page: p.1479
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/22382879
Page: p.1479
DLT: T wave inversion...
Dose limiting toxicities:
T wave inversion (grade 1, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22382879
Page: p.1479
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Disc. AE: Thrombocytopenia, Intracranial hemorrhag...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (2.3%)
Intracranial hemorrhag (grade 5, 2.3%)
Liver failure (grade 5, 2.3%)
Hypertension (2.3%)
Palmar-plantar erythrodysaesthesia syndrome (13.6%)
Proteinuria (6.8%)
Palmar-plantar erythrodysesthesia syndrome (15.9%)
Skin rash (6.8%)
Fatigue (6.8%)
Hypertension (20.5%)
Hypertension (20.5%)
Proteinuria (13.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
DLT: Proteinuria, Hypertension...
Dose limiting toxicities:
Proteinuria (grade 3, 16.7%)
Hypertension (grade 2, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
AEs

AEs

AESignificanceDosePopulation
Proteinuria grade 3, 33.3%
DLT
0.3 mg/kg 1 times / day multiple, oral
MTD
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
Hypertension grade 3, 66.7%
DLT
0.3 mg/kg 1 times / day multiple, oral
MTD
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
Hypertension 10.8%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
unhealthy, ADULT
n = 74
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 74
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
Proteinuria 10.8%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
unhealthy, ADULT
n = 74
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 74
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
Palmar-plantar erythrodysesthesia syndrome 9.5%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
unhealthy, ADULT
n = 74
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 74
Sources:
https://pubmed.ncbi.nlm.nih.gov/21597387
Page: p.1424
T wave inversion grade 1, 16.7%
DLT, Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22382879
Page: p.1479
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/22382879
Page: p.1479
Palmar-plantar erythrodysaesthesia syndrome 13.6%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Proteinuria 13.6%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Palmar-plantar erythrodysesthesia syndrome 15.9%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Hypertension 2.3%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Thrombocytopenia 2.3%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Hypertension 20.5%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Hypertension 20.5%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Fatigue 6.8%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Proteinuria 6.8%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Skin rash 6.8%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Intracranial hemorrhag grade 5, 2.3%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Liver failure grade 5, 2.3%
Disc. AE
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
unhealthy, ADULT
n = 44
Health Status: unhealthy
Condition: hepatocellular carcinoma
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 44
Sources:
https://pubmed.ncbi.nlm.nih.gov/22833179
Page: p.384
Hypertension grade 2, 16.7%
DLT
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
Proteinuria grade 3, 16.7%
DLT
0.25 mg/kg 1 times / day multiple, oral
RP2D
Dose: 0.25 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.25 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/19720910
Page: p.4721
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524
CYPs
33
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1891
 no [Inhibition 50 uM]
CYP2C9
1819
 unlikely [Inhibition 50 uM]
CYP1A2
1692
 weak [Inhibition 50 uM]
CYP3A4
1925
 yes [Inhibition 1 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYPs
33
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY443092
https://www.001chemical.com/chem/search?q=DY443092
1PlusChem LLC
1P0036YH
https://www.1pchem.com/search?query=1P0036YH
A2B Chem
AB48185
http://a2bchem.com/prod/AB48185
AA Blocks
AA0036F1
http://aablocks.com/goods/Goods/detail?id=AA0036F1
AChemBlock
M15676
http://www.achemblock.com/catalogsearch/result/?q=M15676
AK Scientific
SYN1002
https://aksci.com/item_detail.php?cat=SYN1002
AK Scientific
X7465
https://aksci.com/item_detail.php?cat=X7465
Aceschem
ACF019977
https://www.aceschem.com/catalog/search.do?q=ACF019977
Ambeed
A147574
http://www.ambeed.com/search/Search.html?keyword=A147574
Angene
AGN-PC-00A22Y
http://www.angenechemical.com/productshow/AGN-PC-00A22Y.html
ApexBio Technology
A2949
https://www.apexbt.com/catalogsearch/result/?q=A2949
Apollo Scientific
PC402063
http://www.apolloscientific.co.uk/chemical_results.php?qstext=PC402063&product_group=%25&search_fieldname=header_search
AstaTech
42256
http://astatechinc.com/CPSResult.php?CRNO=42256
Axon MedChem
1638
https://www.axonmedchem.com/product/1638
BLD Pharm
BD166190
http://www.bldpharm.com/search/Search.html?keyword=BD166190
BOC Sciences
796967-16-3
http://www.bocsci.com/description.asp?cas=796967-16-3
BioSynth
J-503186
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/J-503186
Cayman Chemical
13653
http://www.caymanchem.com/app/template/Product.vm/catalog/13653
Chem Scene
CS-0115
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0115
ChemShuttle
101005
https://www.chemshuttle.com/catalogsearch/result/?q=101005
Combi-Blocks
QE-2199
http://www.combi-blocks.com/cgi-bin/find.cgi?QE-2199
Excenen
EX-A014
http://www.excenen.com/searchresultlist.php?id=EX-A014
Exclusive Chemistry
2119
http://www.exchemistry.com/chem-catalog/product-2119.html
Fluorochem
432317
http://www.fluorochem.co.uk/Products/Product?code=432317
Fluorochem
510942
http://www.fluorochem.co.uk/Products/Product?code=510942
Hairui
HR33127
http://www.hairuichem.com/en/product/search.do?q=HR33127
KeyOrganics
AS-16177
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16177
Lab Network
LN01288485
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01288485
Lab Seeker
SC-87820
http://www.labseeker.com/search.php?keywords=SC-87820&category=0
LabSeeker
SC-87820
http://www.labseeker.com/search.php?keywords=SC-87820&category=0
Matrix Scientific
125315
http://www.matrixscientific.com/125315.html
MedChem Express
HY-50751
https://www.medchemexpress.com/search.html?q=HY-50751&ft=&fa=&fp=
MolPort
MolPort-009-679-408
https://www.molport.com/shop/molecule-link/MolPort-009-679-408
Molcore
MC443092
http://www.molcore.com/CatMC443092.html
MuseChem
I004909
https://www.musechem.com/product/I004909.html
PI Chemicals
PI-35199
http://www.pipharm.com/catalog_products/PI-35199.html
Ryan Scientific
Lacosamide
https://ryansci.com/products?q=Lacosamide&list_q=&search_type=exact
Selleck Chemicals
S1003
http://www.selleckchem.com/search.html?searchDTO.searchParam=S1003
ShangHai Biochempartner
BCP000073
http://www.biochempartner.com/search_BCP000073
ShangHai Biochempartner
BCP01726
http://www.biochempartner.com/search_BCP01726
SynQuest
4H53-3-07
http://www.synquestlabs.com/search-result.html?q=4H53-3-07
SynQuest
63827
http://www.synquestlabs.com/search-result.html?q=63827
Synthonix
15019
https://synthonix.com/catalogsearch/result/?q=15019
Tetrahedron
TS91680
http://www.thsci.com/search.do?q=TS91680
Toronto Research Chemicals
L466450
https://www.trc-canada.com/product-detail/?CatNum=L466450
Toronto Research Chemicals
S686595
https://www.trc-canada.com/product-detail/?CatNum=S686595
Vesino Industrial Co Ltd
VZ31170
http://www.vsnchem.com/search.do?a=s&psize=20&q=VZ31170
eMolecules
31507650
https://orderbb.emolecules.com/search/#?query=31507650
eMolecules
48864973
https://orderbb.emolecules.com/search/#?query=48864973
eMolecules
72977591
https://orderbb.emolecules.com/search/#?query=72977591
eNovation Chemicals
D782665
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D782665&searchbtn.x=0&searchbtn.y=0
mcule
MCULE-4034055704
https://mcule.com/MCULE-4034055704/
PubMed

PubMed

TitleDatePubMed
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
2006 Apr
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
2006 Apr
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
2007 Apr 5
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
2009 Jul 30
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
2009 Jun
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.
2010 Nov
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
2015 Dec
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
2015 Jan 10
Patents

Patents

08759538
1
JP2011525241A
1
JP4810427B2
1
US20040235892
1

Sample Use Guides

In Vivo Use Guide
Linifanib 17.5 mg once daily.
Route of Administration: Oral
In Vitro Use Guide
Linifanib (ABT-869) is a receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 uM/L) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-beta, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells).
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:31:41 UTC 2023
Edited
by admin
on Sat Dec 16 16:31:41 UTC 2023
Record UNII
CO93X137CW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LINIFANIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
RG-3635
Code English
LINIFANIB [USAN]
Common Name English
UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-
Systematic Name English
1-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-3-(2-FLUORO-5-METHYLPHENYL)UREA
Systematic Name English
A-741439
Code English
ABT-869
Code English
linifanib [INN]
Common Name English
Linifanib [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
NCI_THESAURUS C93259
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
FDA ORPHAN DRUG 240807
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
FDA ORPHAN DRUG 248007
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
Code System Code Type Description
WIKIPEDIA
LINIFANIB
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
USAN
UU-147
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
PUBCHEM
11485656
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
FDA UNII
CO93X137CW
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
INN
9195
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
SMS_ID
100000126073
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
EVMPD
SUB33027
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
NCI_THESAURUS
C71759
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
EPA CompTox
DTXSID40229834
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
CAS
796967-16-3
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
DRUG BANK
DB06080
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
ChEMBL
CHEMBL223360
Created by admin on Sat Dec 16 16:31:41 UTC 2023 , Edited by admin on Sat Dec 16 16:31:41 UTC 2023
PRIMARY
Related Record Type Details
MITOGEN-ACTIVATED PROTEIN KINASE 11
TARGET -> INHIBITOR
Related Record Type Details
Structure of A-849529
METABOLITE ACTIVE -> PARENT
Active: CLK2, CSF1R, DYRK1A, FLT3, GSK3A, GSK3B, JAK2, JAK3, KDR, LIMK1, MAP4K2, MAP4K4, PRKACA, PRKX, ROCK1, STK12, STK6, TAO1, CLK4, MET, PLK4, PLK3, ROCK2, SGK, MARK3, STK3, CDC7, CDK2, CSNK1G2, IRAK3, IRAK4, MINK, MKNK2, RPS6KA5, RPS6KB1, CDC2, CSNK2A1, DYRK3, HIPK4, KIAA1811, MAP4K5, TOPK, CSNK1D, SRPK1, ZAK, PRKG1, PRKG2, FLT4, MARK2, PASK, CDK5
IN-VITRO
Structure of A-849529
METABOLITE ACTIVE -> PARENT
IN-VIVO
PLASMA
Related Record Type Details
Structure of LINIFANIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966